helpingpals
Member
- Joined
- Aug 9, 2011
- Messages
- 16
- Reason
- Other
- Country
- US
- State
- Georgia
- City
- Atlanta
Wall Street Webcasting - Neuralstem, Inc.
If you go to the link and register (it's free) just make up a company name, I just put in ALS, you can listen to the podcast and advance through the slides. The first half of the podcast mostly discusses the trial taking place at emory. At about the 9:55 mark he states that 8 of the 10 surviving patients have either not gotten worse or showed improvement. Keep in mind 2 patients have passed, 1 due to a unrelated heart condition and one due to respiratory failure as a result of his ALS progression.
Yes as Richard Garr acknowledges this is a small sample group and there is no control group receiving placebos. That being said it is still encouraging and some positive news for a change.
Dr. Feldman will be presenting all of the data which includes safety as well as the secondary end points which measures muscle strength in multiple muscles, FVC, FRS, spasticity and a few other measurements. It sounds as though after she presents the info it will be published as well. I am eagerly anticipating the opportunity to review the published data, in particular the secondary end points data.
If you go to the link and register (it's free) just make up a company name, I just put in ALS, you can listen to the podcast and advance through the slides. The first half of the podcast mostly discusses the trial taking place at emory. At about the 9:55 mark he states that 8 of the 10 surviving patients have either not gotten worse or showed improvement. Keep in mind 2 patients have passed, 1 due to a unrelated heart condition and one due to respiratory failure as a result of his ALS progression.
Yes as Richard Garr acknowledges this is a small sample group and there is no control group receiving placebos. That being said it is still encouraging and some positive news for a change.
Dr. Feldman will be presenting all of the data which includes safety as well as the secondary end points which measures muscle strength in multiple muscles, FVC, FRS, spasticity and a few other measurements. It sounds as though after she presents the info it will be published as well. I am eagerly anticipating the opportunity to review the published data, in particular the secondary end points data.